fda ruling on semaglutide alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA's Removal of Semaglutide and

Medical weight loss protocols with flexible plans tailored to your goals.

We will continue to monitor the phenomenal up-take of GLP-1 drugs (recognizing its growing pipeline shown in the chart above) and patients perspectives of the use of these medications both those people prescribed them to treat medical obesity and those consumers willing to pay for them out-of-pocket

Hair loss with GLP-1 meds like Wegovy is due to telogen effluvium

To report a case of non-arteritic ischemic optic neuropathy (NAION) in an otherwise healthy patient treated with Glucagon-Like Peptide-1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide